Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2559-2565

  Johnson, Korey R ^a   Young, Kristy K ^a   Weimin, Fan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; COLCHICINE; FLUOROURACIL; HYDROXYUREA; NOCODAZOLE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P21; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; G1 PHASE; HUMANS; HYDROXYUREA; KB CELLS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RAF; S PHASE; TUMOR CELLS, CULTURED;

EID: 0032882044     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Devita, V. T. Principles of chemotherapy. In: V. T. Devita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology. Ed. 4, pp. 276-292. Philadelphia: J. B. Lippincott Co., 1993.
2. Sartorelli, A. C. Some approaches to the therapeutic exploitation of metabolic sites of vulnerable neoplastic cells. Cancer Res., 29: 1019-1032, 1969.
3. Frei, E., III. Clinical studies of combination chemotherapy for cancer. In: T-C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, Vol. 1, pp. 103-108. San Diego: Academic Press, 1991.
4. Fan, W., Johnson, K. R., and Miller, M. C., III. In vitro evaluation of combination chemotherapy against human tumor cells (Review). Oncol. Rep., 5: 1035-1042, 1998.
5. Yarbro, J. W. The scientific basis of cancer chemotherapy. In: M. C. Perry (ed.), The Chemotherapy Source Book, Ed. 2, pp. 1-18. Baltimore: Williams and Wilkins, 1996.
6. Rideout, D. C., and Chou, T-C. Synergism, antagonism, and potentiation in chemotherapy: an overview. In: T-C. Chou and D. C. Rideout (eds.), Synergism and Antagonism in Chemotherapy, Vol. 1, pp. 3-60. San Diego: Academic Press, 1991.
7. Bertino, J. R., and Chou, T-C. Chemotherapy: synergism and antagonism. In: J. R. Bertino (ed.). Encyclopedia of Cancer, Vol. 1, 368-379. San Diego: Academic Press, 1997.
8. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature (Lond.), 22: 665-667, 1979.
9. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
10. Schiff, P. B., and Horwitz, S. B. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry, 20: 3247-3252, 1981.
11. Kumar, N. Taxol induced polymerization of purified tubulin: mechanism of action. J. Biol. Chem., 256: 10435-10441, 1981.
12. Rowinsky, E. K., Donehower, R. C., Jones, R. J., and Tucker, R. W. Microtubule changes and cytotoxicity in leukemia cell lines treated with taxol. Cancer Res., 48: 4093-4100, 1988.
13. Dustin, P. Microtubules. Sci. Am., 243: 66-76, 1980.
14. Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., and Lazarides, E. Taxol-induced mitotic block triggers rapid onset of a p53-independent pathway. Mol. Med., 1: 506-526, 1995.
15. Horwitz, S. B. Mechanism of action of Taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
16. Kung, A. L., Zetterberg. A., Sherwood, A. W., and Schimke, R. T. Cytotoxic effects of cell cycle specific agents: a result of cell cycle perturbation. Cancer Res., 50: 7307-7314, 1990.
17. Donaldson, K. L., Goolsby, G., Kiener, P. A., and Whal, A. F. Activation of p34cdc coincident with Taxol-induced apoptosis. Cell Growth Differ., 5: 1041-1050, 1994.
18. Rowinsky, E. K., Cazenvae, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Inst. Cancer, 82: 1247-1259, 1990.
19. Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., and Paietta, E. Phase I clinical and pharmacokinetics study of Taxol. Cancer Res., 47: 2486-2493, 1987.
20. Holmes, F. A., Walter, R. S., Theriault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Buzdar, A. U., Frye, D. K., and Hortobagyi, G. N. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.
21. Klassen, U., Harstrick, A., Wilke, H., and Seeber, S. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/ folinic acid in the treatment of metastatic breast cancer. Semin. Oncol., 23 (1 Suppl. 1): 44-47, 1996.
22. Paul, D. M., Garrett, A. M., Meshad, M., DeVore, R. D., Porter, L. L., and Johnson, D. H. Paclitaxel and 5-fluorouracil in metastatic breast cancer: The US experience. Semin. Oncol., 23(1 Suppl. 1): 48-52, 1996.
23. Johnson, D. H., Paul, D., and Hande, K. R. Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a Phase II trial. Semin. Oncol., 24 (1 Suppl. 3): s3-22-s3-25, 1997.
24. Vokes, E. E., Stupp, R., Haraf, D., Moran, W., Malone, D., Wenig, B., Sweeney, P., and Weichselbaum, R. R. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin. Oncol., 22 (3 Suppl. 6): 47-52, 1995.
25. Ajani, J. A., Ilson, D. H., and Kelsen, D. P. The activity of paclitaxel in gastrointestinal tumors. Semin. Oncol., 22 (5 Suppl. 12): 46-53, 1995.
26. Johnson, K. R., Wang, L., Miller, M. C., III, Willingham, M. C., and Fan, W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin. Cancer Res., 3: 1739-1745, 1997.
27. Cheng, L., Zheng, S., Raghunathan, K., Priest, D. G., Willingham, M. C., Norris, J. S., and Fan, W. Characterization of Taxol-induced apoptosis and altered gene expression in breast cancer cells. Cell. Pharmacol., 2: 249-257, 1995.
28. Fan, W., Cheng, L., Norris, J. S., and Willingham, M. C. Glucocorticoids selectively inhibit Taxol-induced apoptosis in a human breast cancer cell line. Cell. Pharmacol., 3: 435-440, 1996.
29. Fan, W., Everett, E. T., Tang, C., Cooper, T., Fang, Q., Bhalla, K., and Norris, J. S. Glucocorticoid-mediated inhibition of Taxol-induced apoptosis leiomyosarcoma cells. Cell. Pharmacol., 1: 205-212, 1994.
30. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
31. Carmichael, J., Degraff, W. G., Gadzar, A. F., Minna, J. D., and Mitchell, J. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 935-942, 1987.
32. Fan, W., Schandl, C. A., Cheng, L., Norris, J. S., and Willingham, M. C. Glucocorticoids modulate paclitaxel cytotoxicity in human solid tumor cells. Cell. Pharmacol., 3: 343-348, 1996.
33. Schandl, C. A., Priest, D. G., and Willingham, M. C. Phosphorylation of bcl-2 is a cell cycle-regulated event. Cell. Pharmacol., 3: 367-372, 1996.
34. Haldar, S., Jena, N., and Croce, C. M. Inactivation of bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA, 92: 4507-4511, 1995.
35. Haldar, S., Chintapalli, J., and Croce, C. M. Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res., 56: 1253-1255, 1996.
36. Blagosklonny, M., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. M. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
37. Blagosklonny, M. V., Giannakakou, P., El-Deiry, W. S., Kingston, D. G. I., Higgs, P. I., Neckers, L. M., and Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
38. Tishler, R. B., Lamppu, D. M., Park, S., and Prince, B. D. Microtubule-active drugs Taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res., 55: 6021-6025, 1995.
39. WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
40. Manfredi, J. J., and Horwitz, S. B. Paclitaxel: an anitimitotic agent with a new mechanism of action. Pharmacol. Ther., 25: 83-125, 1984.
41. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
42. Willingham, M. C., and Bhalla, K. Trasnsient mitotic phase localization of bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J. Histochem. Cytochem., 42: 441-450, 1994.
43. Milas, L., Hunter, N. R., Kurdoglu, B., Mason, K. A., Meyn, R. E., Stephens, L. C., and Peters, L. J. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother. Pharmacol., 35: 297-303, 1995.
44. Kano, Y., Akutsu, M., Tsunoda, S., Suzuki, K., and Yazawa, Y. In vitro schedule dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cell. Chemother. Pharmacol., 37: 525-530, 1996.
45. Kano, Y., Akutsu, M., Tsunoda, S., Ando, J., Matsui, J., Suzuki, K., Ikeda, T., Inoue, Y., and Adachi, K. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br. J. Cancer, 74: 704-710, 1996.